![Complement C1qA polymorphism associates with freedom from progression in follicular lymphoma patients who achieve a CR after anti-CD20 therapy. Progression-free survival logrank curves were plotted by C1qA[276] AA and AG vs GG genotype. Cheson criteria were used to estimate complete clinical remission after one round of anti-CD20 therapy.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/106/11/10.1182_blood.v106.11.778.778/2/778.jpeg?Expires=1747121850&Signature=yixnwO7XsJZ80yKb7Sj6FgpUF-91CtsXpL9ysczrppCuaEsxC~IJDB7AwcGQPJin3dUmdR8PWXkNtGYl4lJDxQl1aVcE9AQt2WpAv6K1ndKTOaGGQv8JqPIdCvQ8tRYWkgagz9d8T~oEyaylNKEwRfEM7weowoZgUV-VEci2moGkSJxowBfHspscgo~9O3WqoRT5b8mJbJPc~jNQYvbznO3L94Iwo~QE1WdpppE1LKlvMt7M9xXLj8Odadvpmrc46DBPBW3-D3d~raHX9CGHaiT2lHIGiTn5uXKvdBhuVp0UHLsA8CWWznKrBk-iIQoYXHDKoRlbL7El5BpBLHU5lw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Complement C1qA polymorphism associates with freedom from progression in follicular lymphoma patients who achieve a CR after anti-CD20 therapy. Progression-free survival logrank curves were plotted by C1qA[276] AA and AG vs GG genotype. Cheson criteria were used to estimate complete clinical remission after one round of anti-CD20 therapy.
